A Multicenter Prospective Study Evaluating Efficacy and Safety of a Single-incision Sling Procedure for Stress Urinary Incontinence

• Published in: Journal of minimally invasive gynecology Vol. 28; no. 1; p. 93
• Main Authors: Erickson, Ty, Roovers, Jan-Paul, Gheiler, Edward, Parekh, Mitesh, Parva, Mohamad, Hanson, Craig, McCrery, Rebecca, Tu, Le Mai
• Format: Journal Article
• Language: English
• Published: United States 01.01.2021
• Subjects: Adult; Aged; Canada - epidemiology; Cohort Studies; Female; Follow-Up Studies; Humans; Middle Aged; Postoperative Complications - epidemiology; Product Surveillance, Postmarketing; Reoperation - statistics & numerical data; Suburethral Slings - adverse effects; Surveys and Questionnaires; Treatment Outcome; United States - epidemiology; Urinary Incontinence, Stress - epidemiology; Urinary Incontinence, Stress - surgery; Urologic Surgical Procedures - adverse effects; Urologic Surgical Procedures - instrumentation; Urologic Surgical Procedures - methods; Canada; United States; Surgery; Efficacy; Minimal invasive; Stress urinary incontinence; Safety; Postmarketing study; Single-incision midurethral sling surgery
• ISSN: 1553-4669
• DOI: 10.1016/j.jmig.2020.04.014

The aim of the Altis 522 study was to compare the safety and efficacy of the Altis Single-Incision Sling System (SIS) (Coloplast, Minneapolis, MN) with standard midurethral transobturator and/or retropubic slings through 36 months. In this report, we present data through 12 months of follow-up. Postmarket, prospective, multicenter, nonrandomized cohort design. The study was performed at 23 hospitals in the United States and Canada. Adult female patients with stress urinary incontinence (SUI) clinically indicated for an incontinence sling were treated (n = 355). Altis SIS was compared with any Food and Drug Administration-cleared transobturator or retropubic sling. Collected measures included device- and/or procedure-related serious adverse events, relevant nonserious and all adverse events, and revision surgery. Objective efficacy measures included 24-hour pad weight, dryness (defined as pad weight ≤4.0 g), and cough stress test. Subjective outcome measures included patient global impression of improvement, urogenital distress inventory, Incontinence Impact Questionnaire-Short Form, Surgical Satisfaction Questionnaire, and visual analog scale for pain. At 12 months, 24-hour pad weight success (≥50% reduction), negative cough stress test, patient global impression of improvement, urogenital distress inventory, and Incontinence Impact Questionnaire-Short Form appeared similar between groups. Through 12 months, 2 subjects in the Altis group and 3 subjects in the comparator group experienced a serious device- and/or procedure-related adverse event. In the Altis group, 1 subject (0.5%) experienced a device revision, and 1 subject (0.5%) had the device explanted. In the comparator group, 7 subjects (4.1%) experienced a device revision, and 1 device (0.6%) was explanted before the 12-month visit. The occurrence of relevant nonserious procedure and/or device-related adverse events was similar between groups. At 12-months follow-up, safety and efficacy appeared similar between Altis SIS and standard transobturator and retropubic midurethral slings.